Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ | Biotech | Oncology / Cancer therapies
Free
No email, no account, no signup.
Pulling latest news for Syndax Pharmaceuticals, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Oncology / Cancer therapies
Market Cap
$1.8B
We're already tracking Syndax Pharmaceuticals, Inc. — here are the latest events we've registered

Recent News

  • On April 30, 2026, the company reported first-quarter 2026 financial results with total revenue of $64.9 million, representing a 224% year-over-year increase. This growth was primarily driven by strong commercial uptake of its approved medicines, Revuforj and Niktimvo.
Want to know how this news affects Syndax Pharmaceuticals, Inc.? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Syndax Pharmaceuticals, Inc. will be delivered in the same format.
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Syndax Pharmaceuticals, Inc. (SNDX)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.